H2020Индивидуална стипендия2020–2022

SALMYB · MYB rearrangements in Adenoid Cystic Carcinoma: protagonists or secondary characters?

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2020-10-19 → 2022-10-18
Финансиране от ЕС
212 934 €
Участници
1
Схема
MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Аденоидният кистичен карцином е рядък рак, който се развива в слюнковите жлези или гърдите. Анализът на генетичните му особености помага да се разбере защо болестта протича различно в различните органи и защо някои пациенти имат по-лоша прогноза.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

MYB rearrangements in Adenoid Cystic Carcinoma: protagonists or secondary characters?

Adenoid cystic carcinoma (ACC) is a relatively rare but life-threatening cancer that occurs mainly in the glands that produce our saliva. However, even though it is more common in salivary glands, ACC can develop in many other organs, including the breast. Salivary gland ACC is considered a difficult cancer to manage and to predict the outcome of the disease in any one patient. The main issues are the risks of late recurrences (more than 10 years after the initial diagnosis) and dissemination to other parts of the body (distant metastasis), including lung, bones and brain. Also, a major problem is the lack of drugs that have a significant impact on disease progression for patients with advanced disease. Patients diagnosed with breast ACC, on the other hand, have a better chance of remaining free of disease for longer periods or never experiencing relapse or dissemination. Scientists still don’t fully understand why ACC in the salivary glands and the breast have different behaviours. Rare cancers, such as ACC, combine the challenges of being both a rare disease (limited scientific data and professional expertise) and cancer (complex tumour biology and resistance to conventional therapies). In many cases, patients with rare cancers have to deal with uncertainties from diagnosis to treatment. Being diagnosed with a rare cancer usually means that it is harder to find doctors who have expertise (often having to travel long distances to access treatment) and, due to the lack of scientific evidence, doctors disagree more often regarding the best treatment available. For physicians, rare cancers are more difficult to handle: there is less evidence to support clinical decisions and, in many cases, less personal experience. SALMYB is a basic-science research project designed to expand our knowledge of this disease. ACC has an associated, recurrent molecular event, chromosomal translocation. This means that a piece of one chromosome, at a specific gene sequence, breaks off and attaches to another chromosome, at another specific gene sequence. In ACC the main genes involved with the translocation are MYB and NFIB. To date we do not understand the full implications of this translocation and the biological implications of the joining of these two genes, however, it is thought that the MYB gene may allow cells to maintain an undifferentiated status, more embryonic-like,which would allow tumours to form, grow and migrate to other sites in the body. Our investigation, studying the biological impacts of the translocation, contributes to the understanding of ACC development benefiting patients suffering from this rare form of cancer at different primary sites.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Adenoid cystic carcinoma (ACC) is both a rare disease (limited scientific data and professional expertise) and a cancer (complex tumour biology and evasion of conventional therapies). Clinical behaviour differs depending on primary tumour site; salivary gland ACC has poorer prognosis than breast ACC. A majority of ACC harbour MYB rearrangements resulting from chromosomal translocations, with the fusion of MYB and NFIB or MYBL1 and NFIB being the most frequent. The role of translocations in tumourigenesis and whether cells from different primary sites respond differently has not been determined. Identification of specific cell types carrying the translocation and location within the tumour microenvironment might enable development of MYB target-therapies. Our main objective is to elucidate the function of MYB rearrangements in normal salivary and mammary gland cells and the expression of the novel fusion genes in salivary gland and breast ACC. Normal human cells will be transfected with MYB-NFIB and MYBL1-NFIB fusion transcripts and fusion negative, fusion positive and combinations of cells will be compared in terms of cell morphology, differentiation, proliferation, migration and invasion. 3D models, more closely mimicking an in vivo tumour, will be compared to monolayer cultures. In situ localisation of MYB-NFIB and MYBL1-NFIB in salivary gland and breast ACC will be assessed using a novel technology, BaseScope. This ambitious research project will determine the consequences of MYB rearrangements using state-of-the-art methods in molecular and cellular biology, genetic and tissue engineering and pathological anatomy. The project has clear translational potential with social, cultural and economic impacts. Transfer of results to other cancers harbouring MYB rearrangements (eg leukaemia, colon cancer) and our methods in assessing other tumours characterised by chromosomal translocations, eg prostate, colorectal and non-small-cell lung cancer, are further outcomes.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз